2026 / 04

DOI: 10.24075/brsmu.2026.044
Copyright: © 2026 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Construction and characterization of the attenuated recombinant influenza virus strains expressing human interleukin 1β

Romanovskaya-Romanko EA , Ozhereleva OO , Plotnikova MA , Altuhov AS , Stukova MA
About authors

Smorodintsev Research Institute of Influenza, St. Petersburg, Russia

Correspondence should be addressed: Ekaterina A. Romanovskaya-Romanko
Professora Popova, 15/17, St. Petersburg, 197022, Russia; ur.xednay@akmormor

About paper

Funding: the study was supported by the Russian Science Foundation (project No. 25-25-00939).

Author contribution: Romanovskaya-Romanko EA — concept, testing, material processing, manuscript writing; Ozhereleva OO — literature review, constructing plasmids, testing, statistical data processing; Plotnikova MA — testing, statistical data processing; Altuhov AS — testing; Stukova MA — approval of the final version of the article.

Compliance with ethical standards: the study was approved by the Ethics Committee of the Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation (protocol No. 07 dated April 23, 2026). Animals were kept under standard conditions in accordance with the Directive 2010/63/ЕС, federal guidelines, and the institutional policy of the Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation.

Received: 2026-07-02 Accepted: 2026-07-28 Published online: 2026-08-17
|
  1. Zhang H, Wang L, An Y, Chen Z. The applications of live attenuated influenza a virus with modified NS1 gene. Mol Ther Nucleic Acids. 2025; 36 (1): 102471.
  2. García-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, Durbin JE, et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology. 1998; 252 (2): 324–30.
  3. Zhang H, Floyd K, Fang Z, Hoffmann FA, Lee A, Froggatt HM, et al. Mucosal vaccination in mice provides protection from diverse respiratory threats. Science. 2026; eaea1260.
  4. Stasakova J, Ferko B, Kittel C, Sereinig S, Romanova J, Katinger H, et al. Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1beta and 18. J Gen Virol. 2005; 86 (Pt 1): 185–95.
  5. Gwinn WM, Kirwan SM, Wang SH, Ashcraft KA, Sparks NL, Doil CR, et al. Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1. Vaccine. 2010; 28 (42): 6901–14.
  6. Lapuente D, Ruzsics Z, Thirion C, Tenbusch M. Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses. Vaccine. 2018; 36 (19): 2712–20.
  7. Hailey KL, Li S, Andersen MD, Roy M, Woods VLJ, Jennings PA. Pro-interleukin (IL)-1beta shares a core region of stability as compared with mature IL-1beta while maintaining a distinctly different configurational landscape: a comparative hydrogen/deuterium exchange mass spectrometry study. J Biol Chem. 2009; 284 (38): 26137–48.
  8. Pulkina A, Vasilyev K, Muzhikyan A, Sergeeva M, RomanovskayaRomanko E, Shurygina AP, et al. IgGκ Signal Peptide Enhances the Efficacy of an Influenza Vector Vaccine against Respiratory Syncytial Virus Infection in Mice. Int J Mol Sci. 2023; 24 (14).
  9. Dittmann M, Hoffmann HH, Scull MA, Gilmore RH, Bell KL, Ciancanelli M, et al. A serpin shapes the extracellular environment to prevent influenza a virus maturation. Cell [Internet]. 2015; 160 (4): 631–43. Available from: http://dx.doi.org/10.1016/j.cell.2015.01.040.
  10. Oleinik V, Plotnikova M, Yolshin N, Romanovskaya-Romanko E. Development and approbation of a quantitative PCR system for studying the expression of endosomal receptors and cytosolic nucleic acid sensors in mice. Med Acad journal. 2025; 1 (1): 90–100.
  11. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA. 2000; 97 (11): 6108–13.
  12. Yildiz S, El Zahed SS, Villalón-Letelier F, Wang Q, Yelleswarapu S, Dawodu G, et al. Re-engineering segment 8 facilitates generation of a versatile live-attenuated influenza A virus vector platform for secretory protein delivery. J Virol. 2026; 100 (5): e0034726.
  13. Gaudino M, Lion A, Sagné E, Nagamine B, Oliva J, Terrier O, et al. The Activation of the RIG-I/MDA5 Signaling Pathway upon Influenza D Virus Infection Impairs the Pulmonary Proinflammatory Response Triggered by Mycoplasma bovis Superinfection. J Virol. 2023; 97 (2): e0142322.
  14. Lin CC, Kuo CT, Cheng CY, Wu CY, Lee CW, Hsieh HL, et al. IL-1 beta promotes A549 cell migration via MAPKs/AP-1- and NF-kappaB-dependent matrix metalloproteinase-9 expression. Cell Signal. 2009; 21 (11): 1652–62.
  15. Harioudh MK, Perez J, Chong Z, Nair S, So L, McCormick KD, et al. Oligoadenylate synthetase 1 displays dual antiviral mechanisms in driving translational shutdown and protecting interferon production. Immunity. 2024; 57 (3): 446–461.e7.
  16. van Rikxoort M, Michaelis M, Wolschek M, Muster T, Egorov A, Seipelt J, et al. Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame. PLoS One. 2012; 7 (5): e36506.
  17. Ozhereleva O, Mustafaeva A, Pulkina A, Plotnikova M, Shuklina M, Shurygina AP, et al. A CXCL10-Expressing Influenza Vector Induces Robust Adaptive Immunity Despite Strong Attenuation. Pharmaceutics. 2026; 18 (6).
  18. Kittel C, Ferko B, Kurz M, Voglauer R, Sereinig S, Romanova J, et al. Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment. J Virol. 2005; 79 (16): 10672–7.